New Data Demonstrate siRNA Delivery to Endothelial Cells In Vivo | GenomeWeb

NEW YORK (GenomeWeb) – A team led by researchers from the Massachusetts Institute of Technology this week published a study describing a new type of nanoparticle capable of delivering siRNAs to endothelial cells, while dodging hepatocytes and immune cells, at doses far lower than previously required.

The siRNA-loaded nanoparticles were also able to mediate highly durable non-liver gene silencing, further opening the door for RNAi as a therapeutic modality in diseases such as cancer and emphysema.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: epigenetic contributors to type 1 diabetes, assembly algorithm to detect structural variations, and more.

The Financial Times looks into how sequencing is moving into the clinic.

Mitochondrial replacement therapy may soon be occurring in the UK, according to the Guardian.

The US House of Representatives has passed the latest version of the 21st Century Cures Act.